Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 1998

View Archived Issues

Shire: six-month highlights

New advances in antiobesity drug therapy reported by Novartis

Dopamine D3 antagonist with improved selectivity, clearance discovered at SB

Dutch academics identify free radical scavengers/xanthine oxidase inhibitors

Schering-Plough prepares arylalkylamines as neurokinin antagonists

Natural nonpeptide inhibitors of protein farnesyltransferase discovered at Merck & Co.

Chugai files for regulatory approval of maxacalcitol

Fujisawa scientists synthesize new series of vasopressin antagonists

FDA grants fast track status for CDP-571

Allelix GI drug moves into the clinic

Tularik/JT establish new collaboration to develop orphan nuclear receptor modulators

Upregulators of LDL receptor in development at Pfizer as hypocholesterolemic agents

New anticonvulsant series developed from SB-204269 at SKB

Ixion receives patent allowance for technology to treat oxalate-related disorders

Synthesis and SAR for piperidine SSNRAs reported at ACS by Parke-Davis/CoCensys

Efficacy of thiazolidinedione rosiglitazone highlighted at diabetes meeting

New T-cell kinase inhibitor presented by Abbott at ACS meeting

MMP inhibitor PGE-2946979 shows good oral antiarthritic activity in rats

Collateral Therapeutics terminates VEGF gene agreement

Exendin-4 inhibits feeding in rats, indicating potential utility for appetite control in humans

Merck's COX-2 inhibitor Vioxx shown safe and effective in clinical trials

KW-5139 effective for reducing gastric stasis following pancreatoduodenectomy

RALES study brought to an early end based on positive impact on mortality

Antisecretory and antiulcer effects of S-0509 characterized in rats

Early clinical results reported for osutidine, an H2 antagonist from Toyama

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...